SAN DIEGO and MEXICO CITY, Dec. 27, 2021 (GLOBE NEWSWIRE) — Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) announced today its subsidiary, Sorrento Therapeutics Mexico (“Sorrento Mexico”), has executed a second contract with a large distributor for the sale and distribution of up to 10 million COVISTIX™ tests for the Mexican market. Sorrento previously announced that Sorrento Mexico had signed a contract with a leading local distributor for up to 5 million COVISTIX tests in Mexico, bringing the total number of tests to 15 million to date.
Related Articles

Sorrento Announces Publication of a Series of Novel SARS-CoV-2 Main Protease (MPRO) Inhibitors for Potential Treatment of COVID-19 Patients Infected With SARS-CoV-2 Variants Of Concern, Including Omicron
SAN DIEGO, Dec. 05, 2021 (GLOBE NEWSWIRE) — Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) today announced the peer-reviewed publication of a series of novel SARS-CoV-2 MPro inhibitors with potent activities for both MPro and cathepsin L, a key host enzyme for SARS-CoV-2 entry into host cells, authored by Dr…. Click here to view original post… […]

Dr. Henry Ji, Sorrento Chairman and CEO, to Participate in the Virtual Cantor Global Healthcare Conference on September 29th, 2021
SAN DIEGO, Sept. 27, 2021 (GLOBE NEWSWIRE) — Sorrento Therapeutics, Inc. (NASDAQ: SRNE, “Sorrento”), announced today that it will participate in the Cantor Virtual Healthcare Conference. Click here to view original post… […]

Sorrento Therapeutics Announces Proposed Public Offering of Common Stock and Warrants
SAN DIEGO, June 28, 2019 (GLOBE NEWSWIRE) — Sorrento Therapeutics, Inc. (Nasdaq: SRNE, ?Sorrento?), a clinical stage, antibody-centric biopharmaceutical company developing new therapies to turn malignant cancers into manageable and possibly curable … […]